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INTRODUCTION
Respiratory diseases make up 68.2% in the structure of 
general disease incidence of children in Ukraine [1]. 
Acute bronchitis is one of the most common diseases of 
the lower respiratory tract among children. It is recorded 
in early childhood more often than in other periods. The 
annual incidence of acute bronchitis is 75 cases per 1000 
children aged from 0 to 12 months and 250 cases per 
1000 children aged from 1 to 3 years old [2]. Every third 
infant wheezes during an episode of viral bronchial tree 
infection [3]. The development of bronchial obstruction 
during acute bronchitis is determined by the anatomical 
and physiological features of the respiratory system, 
the properties of the etiological agent, the nature and 
intensity of the inflammation, which are the result of the 
interaction of genetic, biomedical, social and hygienic 
factors. The tendency for the development of bronchial 
obstruction during acute bronchitis in infants is associat-
ed with perinatal pathology, artificial feeding, hereditary 
predisposition to allergic diseases, bronchial hyperreac-
tivity, passive smoking, physical growth and development 
disorders, deficiency diseases, frequent respiratory viral 
infections [4-10].
THE AIM
The aim of our study was to determine the most informa-
tive immunological and molecular genetic factors which 
reflect the characteristics of the inflammatory process and 
make it possible to predict the development of bronchial 
obstruction during acute bronchitis in infants.
MATERIALS AND METHODS
We have examined 120 children aged from 6 months to 
3 years old with diagnosis of acute bronchitis treated in 
in-patient department of the municipal institution “Dnipro 
city clinical hospital №1”, Dnipro city, Ukraine. There were 
80 patients (66.7%) among them who had the bronchial 
obstruction developed.
The scientific research was carried out in accordance with 
the basic GCP regulations and the Helsinki Declaration, 
approved by the local Bioethics Commission. The parents 
or the guardians of the patients were informed about the 
study and gave their consent to taking part in it.
Clinical examination of the patients was the main re-
search method. Laboratory and instrumental methods 
used to verify the clinical diagnosis were regulated by 
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The aim: To determine the most informative immunological and molecular genetic factors which reflect the characteristics of the inflammatory process and make it possible 
to predict the development of bronchial obstruction during acute bronchitis in infants. 
Materials and methods: 120 children aged from 6 months to 3 years old with acute bronchitis were examined. We determined NF-κB expression level in peripheral blood 
lymphocytes by flow cytometry method, the serum concentrations of interferon-γ, interleukins 4, 12 and 13 by ELISA, total IgE serum level by ECLIA and calculated the relative 
risk (RR) for each of these parameters.
Results: The risk of bronchial obstruction development was high when the relative number of lymphocytes expressing NF-κB was under 49.8% (RR=3.27, 95% CI=2.09-4.92). 
IL-12 serum concentration from 41.35 pg/ml to 173.06 pg/ml (RR=5.35, 95% CI=2.82-9.15) and IL-13 serum concentration from 4.06 pg/ml to 6.71 pg/ml (RR=4.0, 95% 
CI=2.39-6.41) were early predictors of the appearance of wheezing during the disease. The probability of the development of bronchial obstruction was low when the relative 
number of lymphocytes expressing NF-κB was above 49.8% (RR=0.40, 95% CI=0.28-0.62). NF-κB expression level above 0.91 Units (RR=0.20, 95% CI=0.11-0.39), serum 
concentrations of IFN-γ above 9.83 pg/ml (RR=0.50, 95% CI=0.31-0.81), IL-12 above 173.06 pg/ml (RR=0.49, 95% CI=0.30-0.82), IL-13 above 6.71 pg/ml (RR=0.40, 95% 
CI=0.22-0.72) reduced the probability of the appearance of wheezing significantly.
Conclusions: The development of bronchial obstruction during acute bronchitis in infants is associated with the relatively low NF-κB and IL-12 levels, imbalance in IFN-γ and 
IL-13 production.
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the current standards of medical care for children in the 
specialty “Pediatric pulmonology”.
Also we determined NF-κB expression level in periph-
eral blood lymphocytes. Monoclonal antibodies against 
the p65 subunits of the NF-κB molecules (BD Biosciences 
Pharmingen, USA) were used for this purpose. The sam-
ples were analyzed by EPICS XL-MCL Flow Cytometer 
(Beckman Coulter, USA) using System IITM software. The 
study has been performed at the Scientific Research Insti-
tute of the Ukrainian Medical Stomatological Academy, 
Poltava, Ukraine.
The serum concentrations of interferon-γ (IFN-γ), inter-
leukins (IL) 4, 12 and 13 were determined by ELISA using 
appropriate monoclonal antibodies of “Human IFN-γ 
Platinum ELISA BMS228” (eBioscience, USA), “А-8754 
IL-4-ELISA-BEST” (“VECTOR-BEST”, Russia), “Human 
IL-12 (р40/р70) ELISA Kit KHC0121” (Invitrogen, USA), 
“Human IL-13 Platinum ELISA BMS231/3” (eBioscience, 
USA) kits. Total immunoglobulin E (IgE) serum level was 
determined by ECLIA using “Elecsys IgE” REF 04827031 
190” reagent kit (Roche Diagnostics, Switzerland). The 
immunological studies have been performed at the di-
agnostic and treatment center of the Medical Academy, 
Dnipro, Ukraine.
Statistical analysis of the research results was carried out 
by a personal computer using the software package “STA-
TISTICA 6.1” (serial number – AGAR909E415822FA). 
Parametric and non-parametric statistical methods were 
used. We processed 153 clinical, anamnestic, immuno-
logical and molecular genetic parameters, calculated the 
relative risk (RR), the confidence interval (95% CI) for each 
of them and singled out the most informative predictors of 
bronchial obstruction in infants. The differences between 
the compared parameters were considered as statistically 
significant when p ≤ 0.05.
RESULTS AND DISCUSSION
There were 62 boys (77.5%) and 18 girls (22.5%) among 
the patients who wheezed during acute bronchitis. They 
were divided by age in the following way: children aged 
from 6 to 12 months – 50% (40 cases), children aged from 
1 to 2 years old – 36.2% (29 cases), children aged from 2 
to 3 years old – 13.8% (11 cases). The average age of the 
patients was 14.1±0.9 months.
The group of infants, suffering from acute bronchitis 
without wheezing, included 22 boys (55%) and 18 girls 
(45%). There were 11 children aged from 6 to 12 months 
(27.5%), 24 children aged from 1 to 2 years old (60%), 5 
children aged from 2 to 3 years old (12.5%) in the group. 
The average age of the patients was 16.9±1.1 months.
Age structure analysis of acute bronchitis cases in the infants 
(Fig. 1) showed that the maximum risk for the development 
of bronchial obstruction during the disease was observed in 
children aged from 6 to 16 months (RR=1.46, 95% CI=1.09-
1.94) and to a certain extent it could be explained by the 
anatomical and physiological features [11, 12].
Regarding to sex assignment, the male gender was a risk 
factor of bronchial obstruction (RR=1.48, 95% CI=1.04-
2.10), while the female gender was a protector against its 
development (RR=0.48, 95% CI=0.31-0.74). The causes of 
this phenomenon are unclear, although it is reported, that 
the lungs of newborn boys are smaller than the same ones 
of newborn girls [13].
We have singled out the most informative clinical and 
anamnestic predictors of the development of bronchial ob-
struction during the infection process in the infants. Thus, 
wheezing in the child suffering from acute bronchitis was 
associated with the age of his father. The relative risk of the 
development of bronchial obstruction increased in children 
whose fathers were younger than 28 years old (RR=1.53, 95% 
CI=1.16-1.99) and older than 38 years old (RR=2.08, 95% 
Figure 1. Age structure of acute bronchitis in infants
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CI=1.60-2.59). At the same time, the age between 28 and 38 
years old acted as a protector factor (RR=0.47, 95% CI=0.29-
0.74). Interestingly enough, the maternal age did not affect the 
probability of bronchial obstruction development.
Wheezing was associated with birth from repeated (III-V) 
pregnancies (RR=1.67, 95% CI=1.31-1.89), antibiotic treat-
ment during the pregnancy (RR=1.75, 95% CI=1.36-1.98) 
and preterm birth (RR=1.67, 95% CI=1.21-1.82). The high 
risk of bronchial obstruction development was observed in 
children with intrauterine growth restriction (RR=2.92, 95% 
CI=2.02–4.15). However, anemia during the pregnancy prac-
tically excluded the infant’s wheezing (RR=0.29, 95% CI=0.17-
0.92). The risk for the development of bronchial obstruction 
was significantly increased in cases of early cessation of 
breastfeeding (RR=2.23, 95% CI=1.64-3.00). At the same time, 
breast milk feeding for more than 15 months was a protector 
against wheezing (RR=0.29, 95% CI=0.17-0.92). Hereditary 
risk of atopy (RR=2.23, 95% CI=1.52-3.23) and passive smok-
ing (RR=3.77, 95% CI=2.23-5.97) significantly contributed to 
the development of bronchial obstruction in infants. Most of 
our patients (85%) had had acute respiratory tract infections 
(ARTI) before. We determined the maximum risk for wheez-
ing in children who had got ARTI firstly at the age between 
8 and 15 months (RR=1.70, 95% CI=1.25-1.98). Recurrent 
respiratory infections significantly increased the probability 
of the bronchial obstruction development (RR=1.88, 95% 
CI=1.34-2.45). The mention of acute bronchitis with wheez-
ing in the anamnesis (RR=5.35, 95% CI=2.82-9.15) and its 
tendency to be repeated were weighty predictors of the de-
velopment of recurrent bronchial obstruction (RR=4.0, 95% 
CI=2.54-6.53). Also we determined connections between 
wheezing and hypovitaminosis D (RR=1.46, 95% CI=1.01-
1.64), perinatal brain damage (RR=1.87, 95% CI=1.27-2.04), 
obesity (RR=4.58, 95% CI=2.57-7.30). Our results coincide 
with other researchers’ data [4, 7, 8, 14-17].
All our patients fell ill acutely. Cough and fever were 
the first symptoms of the disease. The children, whose 
body temperature at the beginning of the disease was 
under 37.7 °C, made up the group of maximum risk for 
the development of bronchial obstruction (RR=7.50, 
95% CI=3.29-17.06). A fever above 38.9 °C significantly 
reduced the probability of the appearance of wheezing 
(RR=0.32, 95% CI=0.16-0.65). Mild intoxication syn-
drome (RR=5.83, 95% CI=2.95-11.49), its continuance 
under 3 days (RR=3.33, 95% CI=2.01-5.35) and free nasal 
breathing (RR=3.75, 95% CI=2.18-5.61) were the early 
clinical predictors of bronchial obstruction. The absence 
of peripheral microlymphadenopathy syndrome reduced 
the likelihood of wheezing during acute bronchitis in 
infants (RR=0.42, 95% CI=0.24-0.76). The onset of the 
disease was characterized by inflammatory changes in pe-
ripheral blood regardless of the course of acute bronchitis.
EXPRESSION OF NF-κB TRANSCRIPTION FACTOR 
IN INFANTS WITH ACUTE BRONCHITIS
The expression level of NF-κB transcription factor 
reached 0.71±0.02 Units in the children suffering from 
acute bronchitis with wheezing and 0.70 ± 0.03 Units 
in the children suffering from acute bronchitis without 
respiratory disorders (p>0.05). The relative number 
of lymphocytes expressing NF-κB transcription factor 
also did not depend on the course of the disease (table 
1). The results we have obtained probably indicate the 
similarity of the molecular genetic characteristics of 
the inflammatory process in infectious affection of the 
bronchial mucous membrane, which coincides with other 
researchers’ data [18].
The risk of bronchial obstruction development was high 
when the relative number of lymphocytes expressing NF-
κB transcription factor was under 49.8% (RR=3.27, 95% 
CI=2.09-4.92), and the risk was low when the relative 
number of lymphocytes expressing NF-κB was above 49.8% 
(RR=0.40, 95% CI=0.28-0.62). The expression level of the 
nuclear factor κB above 0.91 Units was a protector of the 
development of bronchial obstruction (RR=0.20, 95% 
CI=0.11-0.39). The obtained data can be explained by the 
direct effect of NF-κB transcription factor on Th1-associat-
ed cytokines production, in particular, on the production 
of IFN-γ [18-20].
CYTOKINE PROFILE AND TOTAL IgE IN INFANTS 
WITH ACUTE BRONCHITIS
Th1-ASSOCIATED CYTOKINES
IFN-γ serum concentration in all our patients correspond-
ed to the reference values. However, IFN-γ levels in the chil-
dren suffering from acute bronchitis with wheezing were 
lower than these levels in the children suffering from acute 
bronchitis without respiratory disorders had (0.98±0.18 
pg/ml and 2.17±0.55 pg/ml, respectively; p<0.05). IL-12 
serum concentration in the children suffering from acute 
bronchitis with wheezing did not overstep the limits of the 
reference values and was significantly lower compared with 
the same parameter in the children suffering from acute 
bronchitis without respiratory disorders (144.73±10.30 
pg/ml and 249.00±15.87 pg/ml, respectively; p<0.001). It 
should be noted that IL-12 level in the patients suffering 
from acute bronchitis without wheezing was 1.5 times 
higher than its reference values (table 2).
According to our data, the maximum risk of the devel-
opment of bronchial obstruction during acute bronchitis 
was observed among the children with IL-12 serum con-
centration from 41.35 pg/ml to 173.06 pg/ml (RR=5.35, 
95% CI=2.82-9.15). The probability of the appearance of 
wheezing was significantly reduced when IFN-γ level was 
above 9.83 pg/ml (RR=0.50, 95%  CI=0.31-0.81), IL-12 
level was above 173.06 pg/ml (RR=0.49, 95% CI=0.30-
0.82).
The obtained results confirm the opinion of scientists 
about the failure of the Th1-associated immune response 
in children suffering from acute bronchitis with wheezing. 
Relatively low Th1-associated cytokines serum concentra-
tion and, as a consequence, the formation of Th2-associated 
immune response determine the nature and severity of the 
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inflammatory process underlying in the development of 
bronchial obstruction [21-25].
Th2-ASSOCIATED CYTOKINES AND TOTAL IgE
The serum concentrations of IL-4 and IL-13 in the exam-
ined children corresponded to the reference values and did 
not depend on the course of acute bronchitis. Respectively, 
their levels reached 1.79±0.08 pg/ml and 4.15±0.19 pg/
ml in the children suffering from acute bronchitis with 
wheezing, 1.88±0.08 pg/ml and 4.86±0.43 pg/ml in the 
children suffering from acute bronchitis without respira-
tory disorders (table 3).
It should be noted that 60% of the children suffering from 
acute bronchitis with wheezing and 55% of the children 
suffering from acute bronchitis without respiratory disorders 
(p>0.05) had high serum concentration of total IgE. More-
over, every second patient with high IgE level was a child of 
the first year of life. Perhaps the reasons for that are the phys-
iological features of the immune system, which determine 
significant rise in the sensitivity of infants to both infectious 
environmental factors and allergen exposure [22, 25].
The average serum concentration of total IgE in the children 
suffering from acute bronchitis with wheezing was significantly 
higher than in the children suffering from acute bronchitis 
without respiratory disorders (Table 3). Total IgE level reached 
87.09±11.37 IU/ml and 52.37±9.57 IU/ml, respectively (p<0.05).
The highest risk of the development of bronchial obstruc-
tion during acute bronchitis in the infants was associated 
with IL-13 concentration from 4.06 pg/ml to 6.71 pg/ml 
(RR=4.0, 95% CI=2.39-6.41). At the same time the level 
of this anti-inflammatory cytokine above 6.71 pg/ml pre-
vented the children from the development of bronchial 
obstruction (RR=0.40, 95% CI=0.22-0.72). We think that 
it may be due to IL-13 inhibitory effect on the activity of 
the main transcriptional inflammatory factor NF-κB [26].
CONCLUSIONS
1.  NF-κB expression level predetermines the activity of 
cytokine production and, as a consequence, the course 
of acute bronchitis in infants.
2.  Relatively low NF-κB and IL-12 levels are early predic-
tors of the bronchial obstruction development.
3.  The relatively high activity of NF-κB transcription 
factor and increased IL-12 production at the onset of 
the acute bronchitis considerably reduce the risk of the 
development of bronchial obstruction.
Table 1. NF-κB expression level in infants with acute bronchitis
Parameter
Children suffering from acute bronchitis
with wheezing, n=80
(M±m)
Children suffering from acute bronchitis
without wheezing, n=40
(M±m)
р
Lymphocytes expressing 
NF-κB, % 39.69±1.44 46.12±2.19 > 0.05
NF-κB, Units 0.71±0.02 0.70±0.03 > 0.05
Table 2. The serum levels of Th1-associated cytokines in infants with acute bronchitis
Parameter
Children suffering from acute bronchitis
with wheezing, n=80
(M±m)
Children suffering from acute bronchitis
without wheezing, n=40
(M±m)
Reference value
IFN-γ, pg/ml 0.98±0.18** 2.17±0.55 0-188.9
IL-12, pg/ml 144.73±10.30** 249.00±15.87* 40.4-150
Note: * р≤0.05 – significant difference from the reference value of the parameter
** р≤0.05 – significant difference from the parameter value in children of another group
Table 3. The serum levels of Th2-associated cytokines and total IgE in infants with acute bronchitis
Parameter
Children suffering from acute bronchitis
with wheezing, n=80
(M±m)
Children suffering from acute bronchitis
without wheezing, n=40
(M±m)
Reference 
value
IL-4, pg/ml 1.79±0.08 1.88±0.08 0-4
IL-13, pg/ml 4.15±0.19 4.86±0.43 0-44.4
IgE, IU/ml:
- children aged from 
6 to 12 months;
- children aged from 
1 to 3 years old
87.09±11.37 ** 52.37±9.57
39.84±5.2 *, ** 17.94±2.13 ≤ 15
134.34±19.54 *, ** 65.42±12.37 ≤ 60
Note: * р≤0.05 – significant difference from the reference value of the parameter
** р≤0.05 – significant difference from the parameter value in children of another group
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4.  The development of bronchial obstruction during acute 
bronchitis in infants is associated with imbalance in 
IFN-γ and IL-13 production.
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